ABBV logo

AbbVie

ABBV · What the business does, what can go wrong, and how options sellers approach it

What it does

AbbVie is a global biopharmaceutical company that develops and sells prescription medicines. Its portfolio centers on immunology, with drugs such as Humira, Skyrizi and Rinvoq, and it also has products in oncology, neuroscience and aesthetics. Botox, which came with the Allergan acquisition, is one of its best-known brands.

The company was spun off from Abbott in early 2013.

How it makes money

AbbVie sells branded drugs to patients through pharmacies, hospitals and clinics, usually via wholesalers and insurers. Revenue depends on prescription volume and the prices it negotiates with payers. Aesthetics products such as Botox Cosmetic are often paid for directly by consumers, so they follow a different demand pattern than insured drugs.

Developing new drugs is expensive, so the company spends heavily on research and often adds to its pipeline by acquiring other firms.

Why investors own it

Many investors hold AbbVie for its dividend. Others like its diversified mix of established drugs and newer growth products, and its ability to generate substantial cash flow. Healthcare is also often seen as a defensive sector, since demand for medicine tends to hold up when the economy slows.

What can go wrong

  • Patent expiration: Once a drug loses exclusivity, cheaper biosimilars or generics can take sales quickly. Humira has already gone through this.
  • Drug pricing policy: Government rules on pricing and Medicare negotiation can limit revenue.
  • Pipeline risk: New drugs can fail in trials or be rejected by regulators.
  • Concentration: A few products drive a large share of sales, so trouble with one matters.
  • Litigation and integration: Legal disputes and acquisitions can bring costs and surprises.

What to watch

  • Sales growth of Skyrizi and Rinvoq
  • Pace of Humira erosion from biosimilars
  • Clinical trial results and regulatory decisions
  • Botox and aesthetics demand
  • Drug pricing and Medicare policy changes
  • Dividend coverage by free cash flow
  • Patent expiry dates on key products

Options income angle

Options on ABBV are generally liquid, with many strikes and expirations and tight bid-ask spreads on near-the-money contracts. Implied volatility is usually moderate for a large-cap stock, and it tends to rise around quarterly earnings, clinical trial readouts, regulatory decisions and drug pricing news.

One caution for anyone selling premium: a pipeline failure or policy shock can cause a sharp gap lower that the premium collected may not offset. Selling covered calls also caps upside if good news pushes the stock up quickly.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 20, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

AbbVie reported worldwide net revenues of $61.2 billion for 2025, an increase of 9%, with growth led by Skyrizi and Rinvoq as Humira sales fell sharply. The filing also shows how dependent the company has become on those two drugs, which together made up approximately 42% of total net revenues. Government drug pricing, including the Inflation Reduction Act (IRA) and a January 2026 agreement with the U.S. government, is the main policy issue the filing discusses.

How the business did

  • Operating earnings were $15.1 billion and diluted earnings per share were $2.36. Cash flows from operations were $19.0 billion.
  • Skyrizi net revenues increased 50% and Rinvoq increased 39%, both driven by market share gains and market growth. Humira decreased 49% because of direct biosimilar (copycat biologic) competition after losing exclusivity.
  • Other decliners included Imbruvica (down 14%), Botox Cosmetic (down 4%) and Juvederm Collection (down 15%). Botox Therapeutic rose 15%.
  • Results carried large non-cash charges: $7.4 billion of intangible asset amortization, $6.5 billion from the change in fair value of contingent consideration (amounts owed to sellers of acquired companies that depend on future sales, here driven by higher estimated Skyrizi sales), and $847 million of intangible asset impairment. The effective income tax rate was 36%.
  • The company paid $11.7 billion in dividends and repurchased 3 million shares for $606 million. Remaining buyback authorization was $2.9 billion.

Risks specific to this company

  • Two-drug concentration. Skyrizi and Rinvoq each exceeded 10% of net revenues. Losing patent protection early or facing new competition on either would hit results hard.
  • Government price-setting. Under the IRA, Imbruvica is subject to government-set Medicare prices from 2026, Vraylar and Linzess from 2027, and Botox from 2028. The filing says more products could be selected, which could speed up revenue erosion.
  • Pricing agreement terms. In January 2026 the company agreed to pricing concessions and U.S. investment in exchange for exemptions from tariffs and future price mandates during a three-year period. The filing warns that realized pricing could still be affected by factors outside its control.
  • Distributor and PBM dependence. McKesson, Cardinal Health and Cencora accounted for substantially all U.S. pharmaceutical sales. Pharmacy benefit managers also have significant power over formulary placement (which drugs insurers cover) and rebates.
  • Debt and acquired assets. Long-term debt, including the current portion, was $64,503 million. Developed product rights and other intangibles carried $52.6 billion and goodwill $35.6 billion, so a write-down could be large.
  • Supply and liability exposure. Some raw materials come from single suppliers, and the company self-insures product liability losses. International sales were approximately 24% of net revenues.

What management is watching

  • Revenue growth from key on-market products, listed as Skyrizi, Rinvoq, Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev, Venclexta, Elahere, Botox Cosmetic and Juvederm Collection.
  • The pipeline of approximately 90 compounds, devices or indications, of which approximately 60 are in mid- and late-stage development. Management expects several regulatory submissions, approvals and key trial data readouts in the next 12 months, and names obesity as a new growth area.
  • U.S. investment: the company pledged $100 billion in U.S.-based research and development and capital investments over the next decade, and began building an active ingredient plant in Illinois.
  • Rinvoq exclusivity: a September 2025 settlement with generic makers means no generic Rinvoq tablets are expected before April 2037 in the United States, assuming pediatric exclusivity is granted.
  • Management points investors to revenue at constant currency, a non-GAAP measure that removes exchange-rate effects, and to operating cash flow. It also notes a quarterly dividend increase from $1.64 per share to $1.73 per share and a Moody's upgrade to A2 in February 2026.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 3, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

AbbVie reported net revenues of $17,404 million for the three months ended September 30, 2026, up 10.3% at actual currency rates, with Skyrizi and Rinvoq growing more than 20% while Humira kept shrinking. Profit margins improved against a prior-year quarter that carried large one-time charges. The company also funded its Apogee Therapeutics acquisition largely with new debt.

How the business did

  • Revenue: Nine-month net revenues were $49,396 million, up 10.9% at actual currency rates and 10.1% at constant currency (a measure that strips out the effect of exchange-rate changes). Skyrizi totaled $5,776 million for the quarter, up 22.7%, and Rinvoq totaled $2,706 million, up 23.9%. Humira fell 31.2% to $683 million because of biosimilar (copycat) competition after losing exclusivity. Imbruvica fell 26.1% and Juvederm Collection fell 11.9%.
  • Profit: Gross margin was 75% of revenue versus 66% a year earlier, helped by lower amortization of intangible assets and by the absence of $847 million of impairment charges taken in the 2025 quarter. Acquired IPR&D and milestones (purchased research projects) cost $216 million versus $2,680 million. The effective tax rate was 13% versus 74%.
  • Unusual items: Changes in the fair value of contingent consideration (what the company may owe former owners of acquired businesses, re-estimated each period) cost $829 million in the quarter and $4.7 billion for nine months. The company tied this to higher estimated Skyrizi sales and the passage of time. Nine-month diluted earnings per share were $4.79.
  • Cash and capital return: Operating cash flow for nine months was $14,871 million versus $13,812 million. The company paid $10.6 billion net of cash acquired for acquisitions of businesses, mainly Apogee, and issued $18.0 billion of senior notes. It paid $9.2 billion in dividends and repurchased 5 million shares for $1.1 billion.

What management is watching

  • Dividend and spending: The board raised the quarterly dividend from $1.73 to $1.82 per share, beginning with the payment on February 16, 2027. The company pledged $100 billion in U.S. research and development and capital investment over the next decade, including a North Carolina manufacturing campus and two Illinois facilities.
  • Policy: Under a January 2026 agreement with the U.S. government, AbbVie received a three-year exemption from tariffs and future price mandates. On October 29, 2026, a federal court set aside the selection of Botox for Medicare price-setting that was due to begin in 2028. The government can appeal.
  • Pipeline: Management expects several regulatory submissions, approvals and trial readouts over the next 12 months. Recent items include FDA approval of Skyrizi for Crohn's disease subcutaneous induction in October 2026 and a BLA (a formal application for FDA approval) for etentamig in multiple myeloma. The company also reported that the Epkinly DLBCL-1 trial did not show a statistically significant improvement in overall survival.
  • Financial strength: Moody's upgraded the long-term credit rating to A2 in February 2026, and S&P revised its outlook to positive in June 2026. No commercial paper was outstanding at September 30, 2026.

Follow ABBV in Kortex

The Kortex app shows ABBV's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.